These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31830679)

  • 1. Temporal correlation between serum CH
    Yanagidaira M; Nishida Y; Yokota T
    Clin Neurol Neurosurg; 2020 Feb; 189():105630. PubMed ID: 31830679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
    Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
    Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
    Greenwood GT; Lynch Z
    Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
    Uzawa A; Ozawa Y; Yasuda M; Kuwabara S
    J Neuroimmunol; 2020 Dec; 349():577424. PubMed ID: 33068973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
    Uzawa A; Kuwabara S
    Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
    Xiao H; Wu K; Liang X; Li R; Lai KP
    Front Immunol; 2021; 12():715036. PubMed ID: 34456922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab in refractory myasthenic crisis.
    Yeo CJJ; Pleitez MY
    Muscle Nerve; 2018 Aug; 58(2):E13-E15. PubMed ID: 29524335
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab: A Review in Generalized Myasthenia Gravis.
    Dhillon S
    Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eculizumab led to beneficial clinical course in a patient with generalized myasthenia gravis who developed COVID 19-associated pneumonia].
    Kuroda Y; Watanabe G; Satou K; Ono H; Tsukita K; Suzuki Y
    Rinsho Shinkeigaku; 2024 Feb; 64(2):109-112. PubMed ID: 38281749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    Jiao L; Li H; Guo S
    J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience of using eculizumab in refractory myasthenia gravis].
    Stepanova SB; Karpova MI; Vasilenko AF; Domashenko MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(7. Vyp. 2):85-90. PubMed ID: 39175245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    Pane C; Di Stefano V; Cuomo N; Sarnataro A; Vinciguerra C; Bevilacqua L; Brighina F; Rini N; Puorro G; Marsili A; Garibaldi M; Fionda L; Saccà F
    J Neurol; 2024 Sep; 271(9):6209-6219. PubMed ID: 39080054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.